Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients | Zendy

Nicholas Cowley | Zendy; Andrew Owen | Zendy; Sarah C. Shiels | Zendy; Joanne Millar | Zendy; Rebecca Woolley | Zendy; Natalie Ives | Zendy; Husam Osman | Zendy; Paul Moss | Zendy; Julian Bion | Zendy

Open Access

Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients

Author(s) -

Nicholas Cowley,

Andrew Owen,

Sarah C. Shiels,

Joanne Millar,

Rebecca Woolley,

Natalie Ives,

Husam Osman,

Paul Moss,

Julian Bion

Publication year - 2017

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2017.0895

Subject(s) - medicine , valganciclovir , population , ganciclovir , intensive care unit , randomized controlled trial , cytomegalovirus , viral load , mechanical ventilation , valaciclovir , immunology , human cytomegalovirus , viral disease , herpesviridae , virus , environmental health

Latent cytomegalovirus (CMV) infection is present in more than half the adult population, and a viral reactivation (ie, when the virus becomes measurable in body fluids such as blood) can occur in up to one-third of these individuals during episodes of critical illness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research